Last reviewed · How we verify

Usual treatment for ADHD — Competitive Intelligence Brief

Usual treatment for ADHD (Usual treatment for ADHD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central nervous system stimulant. Area: Neurology.

phase 3 Central nervous system stimulant Dopamine transporter Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Usual treatment for ADHD (Usual treatment for ADHD) — Puerta de Hierro University Hospital. Stimulates the brain to increase focus and attention by increasing the levels of certain neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Usual treatment for ADHD TARGET Usual treatment for ADHD Puerta de Hierro University Hospital phase 3 Central nervous system stimulant Dopamine transporter
Ioflupane I 123 IOFLUPANE Ge Hlthcare Inc marketed Radioactive Diagnostic Agent [EPC] Dopamine transporter (DaT) 2023-01-01
Goprelto COCAINE marketed cocaine Sodium-dependent dopamine transporter 2017-01-01
Datscan IOFLUPANE I 123 Ge Hlthcare Inc marketed Radioactive Diagnostic Agent [EPC] Sodium-dependent dopamine transporter 2011-01-01
Vyvanse LISDEXAMFETAMINE Takeda marketed Central Nervous System Stimulant Sodium-dependent dopamine transporter 2007-01-01
Focalin DEXMETHYLPHENIDATE Novartis marketed Central Nervous System Stimulant Sodium-dependent dopamine transporter 2001-01-01
Pemolin PEMOLINE marketed pemoline Sodium-dependent dopamine transporter 1975-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central nervous system stimulant class)

  1. Impax Laboratories, LLC · 2 drugs in this class
  2. Janssen-Cilag International NV · 2 drugs in this class
  3. Alza Corporation, DE, USA · 1 drug in this class
  4. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  5. Eli Lilly and Company · 1 drug in this class
  6. McMaster University · 1 drug in this class
  7. McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · 1 drug in this class
  8. Nanogen Pharmaceutical Biotechnology Joint Stock Company · 1 drug in this class
  9. Novartis · 1 drug in this class
  10. Phytopharm Consulting Brazil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Usual treatment for ADHD — Competitive Intelligence Brief. https://druglandscape.com/ci/usual-treatment-for-adhd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: